IMS 2024 | Final results of the DART4MM study of daratumumab for MRD eradication in myeloma

The DART for myeloma (DART4MM) is a study that was co-financed by Johnson & Johnson. The study is basically on daratumumab as consolidation after autologous stem cell transplantation or first-line therapy multiple myeloma patients. And the hypothesis was to eradicate minimal residual disease present in multiple myeloma patients after a first line of therapy. We used daratumumab for six months in the usual scheduled way. And the first endpoint was progression-free survival after six months. We measured minimal residual disease with next generation flow. Those were patients already in a very good, at least very good, partial response. And the interesting thing is that we had 30% of the patients after six months that achieved an MRD negative status. MRD negativity doesn’t mean, as we know, cure. The unsustained MRD negativity could be better to measure a minimal residual disease, which means to look at other points in the history of the patient and that in which the patient can be MRD negative. So basically patients could relapse after six months but the interesting thing is that we add also an other MRD negativity points in other patients during the 24 month treatment with daratumumab. At the end of 24 months after two years of daratumumab, 30% of the patients were still negative. So, this is a very nice result that means that daratumumab is effective in eradicating the disease in a good proportion of patients.